{
    "clinical_study": {
        "@rank": "109279", 
        "arm_group": {
            "arm_group_label": "Metfomin + irinotecan", 
            "arm_group_type": "Experimental", 
            "description": "Irinotecan 350mg/m\u00b2 q21d + metformin up to 2500mg/d until disease progression, prohibitive toxicity or consent withdrawal"
        }, 
        "brief_summary": {
            "textblock": "MetIri seeks to identify if metformin combined to irinotecan can improve tumor control."
        }, 
        "brief_title": "Metformin Plus Irinotecan for Refractory Colorectal Cancer", 
        "completion_date": {
            "#text": "September 2015", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Colorectal Neoplasms", 
            "Adenocarcinoma"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Adenocarcinoma", 
                "Neoplasms", 
                "Colorectal Neoplasms"
            ]
        }, 
        "detailed_description": {
            "textblock": "MetIri is a two-stage single arm Phase II assessing the role of combination of metformin to\n      irinotecan for colorectal cancer patients already treat with oxaliplatin, fluoropyrimidine,\n      irinotecan and anti-EGFr antibody if Kras wild type."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  18 years or older\n\n          -  Biopsy-proven colorectal adenocarcinoma\n\n          -  Ineligibility for curative intent therapy, e.g., surgery or radiation\n\n          -  Disease progression after oxaliplatin (either adjuvant or palliative),\n             fluoropyrimidine (either adjuvant or palliative), irinotecan, and if Kras wild type a\n             anti-EGFR therapy\n\n          -  Assessable disease according to RECIST v1.1\n\n        Exclusion Criteria:\n\n          -  known hypersensitivity to metformin or irinotecan\n\n          -  SNC metastasis\n\n          -  Acute or chronic severe infection"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "41", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "August 26, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01930864", 
            "org_study_id": "MetIri"
        }, 
        "intervention": [
            {
                "arm_group_label": "Metfomin + irinotecan", 
                "description": "metformin up to 2500mg/d", 
                "intervention_name": "Metformin", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Metfomin + irinotecan", 
                "description": "Irinotecan 350 mg/m\u00b2 IV q21d", 
                "intervention_name": "Irinotecan", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Metformin", 
                "Irinotecan"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "metformin", 
            "colorectal cancer", 
            "chemotherapy"
        ], 
        "lastchanged_date": "April 17, 2014", 
        "location": [
            {
                "contact": {
                    "email": "joaopaulo.oncologia@hcancerbarretos.com.br", 
                    "last_name": "Joao Paulo SN Lima, MD", 
                    "phone": "551733216600", 
                    "phone_ext": "7128"
                }, 
                "contact_backup": {
                    "email": "aryscampos@yahoo.com.br", 
                    "last_name": "Arinilda C Bragagnoli, MD", 
                    "phone": "551733216600", 
                    "phone_ext": "6829"
                }, 
                "facility": {
                    "address": {
                        "city": "Barretos", 
                        "country": "Brazil", 
                        "state": "SP", 
                        "zip": "14784-400"
                    }, 
                    "name": "Barretos Cancer Hospital"
                }, 
                "investigator": {
                    "last_name": "Joao Paulo SN Lima, MD, PhD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "ligaimed@gmail.com", 
                    "last_name": "L\u00edgia T Macedo, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Campinas", 
                        "country": "Brazil", 
                        "state": "S\u00e3o Paulo", 
                        "zip": "1300000"
                    }, 
                    "name": "State University of Campinas"
                }, 
                "investigator": {
                    "last_name": "Ligia T Macedo, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }
        ], 
        "location_countries": {
            "country": "Brazil"
        }, 
        "number_of_arms": "1", 
        "official_title": "Phase II Trial of Metformin Combined to Irinotecan for Refractory Metastatic or Recurrent Colorectal Cancer", 
        "overall_contact": {
            "email": "jpsnlima@yahoo.com.br", 
            "last_name": "Joao Paulo SN Lima, MD", 
            "phone": "551733216600", 
            "phone_ext": "7128"
        }, 
        "overall_contact_backup": {
            "email": "aryscampos@yahoo.com.br", 
            "last_name": "Arinilda C Bragagnoli, MD", 
            "phone": "551733216600", 
            "phone_ext": "6829"
        }, 
        "overall_official": {
            "affiliation": "Barretos Cancer Hospital", 
            "last_name": "Joao Paulo SN Lima, MD, PhD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "Brazil: Ethics Committee", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "September 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Non-Progression at week 12th of treatment", 
            "safety_issue": "No", 
            "time_frame": "12th week"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01930864"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Progression-free survival", 
                "safety_issue": "No", 
                "time_frame": "12th week"
            }, 
            {
                "measure": "Overall Survival", 
                "safety_issue": "No", 
                "time_frame": "12th week"
            }, 
            {
                "description": "Measured by EORTC QLQ C30", 
                "measure": "Quality of life", 
                "safety_issue": "No", 
                "time_frame": "12th week"
            }, 
            {
                "description": "Assessment of toxicity according to CTC 4.0", 
                "measure": "Safety", 
                "safety_issue": "Yes", 
                "time_frame": "12th week"
            }
        ], 
        "source": "Barretos Cancer Hospital", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Barretos Cancer Hospital", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "April 2014", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}